The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Gynecologic Cancers MORE >>

Advances in checkpoint inhibitor therapy have gained speed in cancer care; however, ovarian cancer has yet to see any approved indications for immunotherapy agents, said Lana E. Kandalaft, PharmD, PhD, to an audience at the European Society for Medical Oncology 2018 Immuno-Oncology Congress.

Latest JournalAll Journals >>

The Journal of Targeted Therapies in Cancer February 2019
The Journal of Targeted Therapies in Cancer
MORE >>
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.